P/B
6,4
Trevi Therapeutics
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.
$2.1B
Market Cap • 9/28/2026
2011
(15 years)
Founded
2019
(7 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
—
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
2,2
EPS
—
Market Cap
Market Cap
2,1B
EV
1,7B
EV/Revenue
0
EV/EBITDA
-29,2
EV/EBIT
-29,1
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-8,1%
Total Yield
-8,1%
Payout
0%
Retained Earnings
-360,8M
Profitability
Gross Margin
—
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
0%
Capex/Revenue
0%
Capex/D&A
173,7%
Capex/OCF
-0,5%
SBC/OCF
—
% PPE
0,3%
% Goodwill
0%
ROE
—
ROIC
—
Growth
CAGR Op. Income 5Y
12,1%
CAGR Net Income 5Y
7,8%
CAGR EPS 5Y
-27,9%
CAGR OCF 5Y
10,9%
Leverage
N.D./EBITDA
5,4
Debt/Equity
0%
Current Ratio
37,3
Quick Ratio
36,5
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!